Mucopolysaccharidosis type 3 (Sanfilippo)
On ABGC's listListed on the ABGC Self-Study GuideLog in to starLast updated Nov 15, 2026
A child with normal appearance develops severe behavioral problems, sleep disturbance, and progressive dementia. Mild coarse features develop later.
AR; four subtypes, one per lysosomal enzyme of heparan sulfate breakdown: SGSH (IIIA), NAGLU (IIIB), HGSNAT (IIIC), GNS (IIID). Biallelic loss-of-function variants in any one leave heparan sulfate undegraded.
The four enzymes work at separate steps of the lysosomal breakdown of heparan sulfate, so a defect in any one of them leaves heparan sulfate only partly degraded, and it accumulates. That shared substrate is why four genes give one clinical picture: progressive central nervous system degeneration with relatively mild somatic features.
- Variants in SGSH (IIIA, heparan-N-sulfatase): the most common subtype worldwide. p.Arg245His and other variants give rapid progression when homozygous; p.Ser298Pro is an attenuating allele, and homozygotes progress slowly.
- Variants in NAGLU (IIIB, alpha-N-acetylglucosaminidase): the second most common. Homozygous p.Arg297Ter, p.Val334Phe, or p.Pro521Leu give severe disease; in a Dutch cohort, some missense variants occurred only in slowly progressing patients.
- Variants in HGSNAT (IIIC, an acetyltransferase that uses acetyl-CoA) and GNS (IIID, glucosamine-6-sulfatase): rarer, with no genotype-phenotype correlation found.
Across genes, two truncating alleles usually mean faster progression. The behavioral hallmark, with oral behaviors and reduced fear, has been tied to amygdala volume loss, and the severe sleep disturbance to altered melatonin secretion.
Part of lysosomal glycosaminoglycan degradation.
Lysosomal degradation of heparan sulfate, by enzymes that each remove a sugar or a sulfate from the end of the chain, with one (IIIC) adding an acetyl group first.
heparan sulfate → lysosome → one of four steps (the block): heparan-N-sulfatase (A), alpha-N-acetylglucosaminidase (B), acetyl-CoA:alpha-glucosaminide N-acetyltransferase (C), or N-acetylglucosamine-6-sulfatase (D) → further stepwise degradation → free sugars and sulfate
- Accumulates: heparan sulfate alone, measured as raised urine heparan sulfate.
- Missing: the chain's breakdown products; the disease comes from storage, above all in the brain.
- Workbook: 7.I. Other mucopolysaccharidoses
- Predominantly CNS disease
- Severe behavioral problems, sleep disturbance
- Mild somatic features (coarse features, hepatosplenomegaly less prominent)
- Heparan sulfate elevated
- Urine glycosaminoglycans: isolated elevation of heparan sulfate (distinguishes from other MPS types)
- Subtype determined by deficient enzyme activity: A (SGSH, heparan-N-sulfatase), B (NAGLU), C (HGSNAT), D (GNS)
- Molecular confirmation of the relevant gene
- No disease-modifying therapy approved; supportive and symptomatic care
- Manage behavioral problems and sleep disturbance (CNS-predominant disease limits the benefit of enzyme replacement, which does not cross the blood-brain barrier)
- Anticonvulsants for seizures; multidisciplinary developmental, neurologic, and palliative support
"SanfIIIppo": the Roman numeral III is hidden in the name. MPS III is primarily a neurological disorder, with profound neurodegeneration by age 6-10 years and relatively mild somatic features.
4 enzymes, 1 phenotype: Sanfilippo has 4 subtypes (A-D), each caused by a different enzyme deficiency, but all share the same clinical presentation (primarily CNS disease with behavioral problems and hyperactivity).